Deutsche Bank lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $35 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz
- Acadia Pharmaceuticals PWS miss ‘disappointing but expected,’ says Leerink
- Soleno shares jump following competitor Acadia’s trial miss